Clinical trials: Body Weight Control
Obesity
Vagal Blocking for Obesity Control
To determine the safety, efficacy and treatment algorithm(s) of the Maestro System in causing weight loss in obese subjects - This study will provide feasibility data regarding the potential of intra-abdominal vagus nerve…
- Trial name
- NCT00555958
- Testing
- Active, implantable, intra-abdominal vagal blocking medical device
- Where
- 5 sites in Australia, Mexico and 2 more
- Volunteers
- 120 people
- Sponsor
- ReShape Lifesciences
Weight Gain
Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study. Approximately 78 subjects (39 per treatment group) will be randomized into this 16 week study.
- Trial name
- NCT00428168
- Testing
- Betahistine
- Where
- 10 sites in Canada, Israel
- Volunteers
- 36 people
- Sponsor
- OBEcure Ltd.
Cachexia
A Phase 1 Study of AV-380 in Healthy Subjects
This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy subjects of a single dose of AV-380.
- Trial name
- NCT04815551
- Testing
- AV-380
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AVEO Pharmaceuticals, Inc.
Obesity
Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients
To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients (BMI 35,0-39,9 kg/m2).
- Trial name
- NCT01570829
- Testing
- Dietressa
- Where
- 17 sites in Russia
- Volunteers
- 331 people
- Sponsor
- Materia Medica Holding
Type 2 Diabetes, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- SURMOUNT-2 (NCT04657003)
- Testing
- Tirzepatide
- Where
- 75 sites in United States, Argentina and 6 more
- Volunteers
- 938 people
- Sponsor
- Eli Lilly and Company
Obesity
Effects of Repeat Dosing of GSK1521498
The overall purpose of this study is to see whether the drug is safe and well tolerated when given to overweight or obese but otherwise healthy volunteers for 10 days.
- Trial name
- NCT00976105
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Impaired Glucose Tolerance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity, and to assess the…
- Trial name
- NCT01275469
- Testing
- GFT505 80mg
- Where
- 20 sites in France
- Volunteers
- 47 people
- Sponsor
- Genfit
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Obesity, Overweight
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07215559
- Testing
- Macupatide, Eloralintide
- Where
- 42 sites in United States, Argentina and 2 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome, Obesity
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single oral dose.
- Trial name
- NCT01285388
- Testing
- MB12066
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Neuromuscular Blockade
Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)
The purpose of this trial is to evaluate the safety and efficacy of Sugammadex when administered according to actual body weight (ABW) as compared to ideal body weight (IBW) for the reversal of both moderate and deep…
- Trial name
- NCT03346070
- Testing
- Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 207 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Type 2 Diabetes Mellitus
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05184322
- Testing
- T2026, Oral ecnoglutide tablet
- Where
- Australia
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Overweight , Obesity
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07778693
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 760 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Obesity &Amp; Overweight
Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus
This Phase 3 study is designed to evaluate the efficacy and safety of IN-B00009 injection in adults with obesity or overweight without diabetes mellitus
- Trial name
- NCT07192263
- Testing
- IN-B00009
- Volunteers
- 300 people
- Sponsor
- HK inno.N Corporation
Hypertension
Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients
A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension
- Trial name
- NCT00160498
- Testing
- Lercanidipine
- Volunteers
- 180 people
- Sponsor
- UCB Pharma
Overweight and Obesity
Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
This will be a single centre, Phase 1, placebo-control, randomized, double-blind, sequential single and multiple ascending dose study to assess the safety, tolerability, and PK of GMA106 in healthy, overweight or obese subjects.
- Trial name
- NCT05054530
- Testing
- GMA106 Injection
- Where
- Australia
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Gmax Biopharm Australia Pty Ltd.
Sleep Apnea, Obstructive
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index…
- Conditions
- Sleep Apnea, Obstructive, Obesity
- Trial name
- NCT06931028
- Testing
- IBI362
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight and Obesity
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its…
- Trial name
- CONTEMPO (NCT06151964)
- Testing
- AZD9550, AZD9550 and AZD6234
- Where
- 15 sites in Austria, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Body Weight, Body Fat
Effect of Vigiis 101 Lactic Acid Bacteria Powder on Body Weight and Body Fat in Overweight Participants
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (14 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Conditions
- Body Weight, Body Fat, Overweight
- Trial name
- NCT05869799
- Testing
- Vigiis 101 Lactobacillus Capsules
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SunWay Biotech Co., LTD.